Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Breast Neoplasms 42Rectal Neoplasms 31Colorectal Neoplasms 31Pancreatic Neoplasms 30Neoplasms 26Stomach Neoplasms 20Neoplasm Metastasis 17Colonic Neoplasms 13Unspecified Adult Solid Tumor, Protocol Specific 12Esophageal Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Solid Tumor 7Biliary Tract Neoplasms 7Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Liver Neoplasms 4Carcinoma, Hepatocellular 4Bile Duct Neoplasms 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Appendiceal Neoplasms 3Anus Neoplasms 3Adenocarcinoma 3Vaginal Neoplasms 2Uterine Cervical Neoplasms 2

Interventions

veliparib 1relacorilant 1pembrolizumab 1fludarabine phosphate 1fludarabine 1Temozolomide 1Mesna 1Cyclophosphamide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adrenal Cortex Neoplasms × Capecitabine × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡